Clinical Trial Update: Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis [Phase 2]

View source ↗

Summary

Phase 2 safety and pharmacokinetics study in multidrug-resistant refractive tuberculosis was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Tuberculosis | Phase 2 | Status: TERMINATED | Results posted: 2021-11-11